Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress
Watch Dr. Parekkadan’s interview at the World Advanced Therapies & Regenerative Medicine Congress in London here!
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel delivery approaches to cell therapy.
Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.